Time to next pulmonary exacerbation · children and adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next pulmonary exacerbation · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next pulmonary exacerbation · adolescents and adults with cystic fibrosis
Digital technology probably leads to higher time to next pulmonary exacerbation compared with usual care (moderate certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adolescents and adults with cystic fibrosis
Digital technology showed no clear difference in number of pulmonary exacerbations: number of participants… compared with usual care (moderate certainty).
1 finding from 1 review
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants receiving nasal CPAP
Bubble showed no clear difference in bronchopulmonary dysplasia compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
Caffeine showed no clear difference in bronchopulmonary dysplasia/chronic lung disease: defined as 28 days… compared with other methylxanthines (low certainty).
1 finding from 1 review
RR 1.4 [0.92, 2.11]
Studies not reported
Low
c) Developmental delay more than two SDs below population mean on a standardized test of development: cognitive delay № of participants: 79(1 RCT) · preterm infants
It is very uncertain whether caffeine changes c) Developmental delay more than two SDs below population mean on a… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.17 [0.02, 1.37]
Studies not reported
Very low
c) Developmental delay more than two SDs below population mean on a standardized test of development: language delay № of participants: 79(1 RCT) · preterm infants
It is very uncertain whether caffeine changes c) Developmental delay more than two SDs below population mean on a… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.76 [0.37, 1.58]
Studies not reported
Very low
c) Developmental delay more than two SDs below population mean on a standardized test of development: motor delay № of participants: 79(1 RCT) · preterm infants
It is very uncertain whether caffeine changes c) Developmental delay more than two SDs below population mean on a… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.5 [0.13, 1.96]
Studies not reported
Very low
Pulmonary embolism · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).
1 finding from 1 review
Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics may leads to lower pulmonary exacerbations: frequency of one or more hospital admissions compared with placebo (low certainty).
1 finding from 1 review
Need for antibiotics see pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: aztreonam lysine for inhalation probably leads to lower pulmonary exacerbations: need for additional antibiotics compared with tobramycin (moderate certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · adults and children aged over 12 with CF and P aeruginosa
Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty).
1 finding from 1 review